theMednetRegister

ACR 2024   

Questions discussed in this category

What is your approach to screening patients with sJIA for associated lung disease?
Do you universally screen? What prompts you to screen when you do? This question is part of our collaboration with ACR Convergence 2024 to Continue t...
2 Answers available
What is the most impactful career advice you have received from a colleague or mentor?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeting. This question was inspired by the ...
6 Answers available
What strategies or initiatives do you think could be most effective in addressing the rheumatology workforce shortage?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeting. This question was inspired by...
3 Answers available
How do you screen rheumatoid arthritis patients for lung disease (modality, frequency, patient selection)?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspired by the...
5 Answers available
What is the role of the rheumatologist in recommending and providing GLP-1 medications to their patients given the benefits across many disease domains including osteoarthritis?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeting. This question was inspired by the ...
1 Answer available
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
What information do you use to make this determination? Do you tend to transition to an oral agent like azathioprine after discontinuation to prevent ...
2 Answers available
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspi...
1 Answer available
Do you continue biologics in sJIA patients who develop lung disease on anti IL-1 or anti IL-6 therapies?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeting. This question was inspired by the ...
2 Answers available


Papers discussed in this category

Autoimmunity reviews, 2021 Apr 19
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
Arthritis & rheumatology (Hoboken, N.J.), 2024 Jul 08
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Rheumatology international, 2023 Apr 18
Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis.
Autoimmunity reviews, 2024 Sep 11
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis.
Life (Basel, Switzerland), 2023 Jul 28
Obesity-Related Knee Osteoarthritis-Current Concepts.
The New England journal of medicine, 2024 Oct 31
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
N Engl J Med, 2020 Feb 13
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
N Engl J Med, 2021 Feb 18
Avacopan for the Treatment of ANCA-Associated Vasculitis.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.